GSK239512

DRUG6 trials

Sponsors

GlaxoSmithKline

Conditions

Alzheimer's DiseaseDementiaMild Cognitive ImpairmentMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingSchizophrenia

Phase 1

An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.

CompletedNCT00474513

GlaxoSmithKlineDementia, Mild Cognitive Impairment

Start: 2007-03-31End: 2008-03-31Updated: 2012-06-04

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

CompletedNCT00675090

GlaxoSmithKlineAlzheimer's Disease

Start: 2008-02-21End: 2009-06-16Updated: 2017-07-07

GSK239512 DDI Study

CompletedNCT01802931

GlaxoSmithKlineMultiple Sclerosis

Start: 2013-01-07End: 2013-04-15Updated: 2017-07-26

Phase 2

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

CompletedNCT01009060

GlaxoSmithKlineSchizophrenia

Start: 2009-12-01End: 2011-08-10Updated: 2017-11-08

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

CompletedNCT01009255

GlaxoSmithKlineAlzheimer's Disease

Start: 2009-11-02End: 2010-11-10Updated: 2017-04-13

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

CompletedNCT01772199

GlaxoSmithKlineMultiple Sclerosis, Relapsing-Remitting

Start: 2013-02-28End: 2014-09-30Updated: 2016-08-16

Related Papers

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Journal of Neurology2016-11-25109 citations